AbbVie (NYSE:ABBV) Stock Price Down 2.1% - What's Next?

Key Points

• AbbVie shares fell 2.1% to about $288.66 on elevated trading volume, despite recent strong quarterly results and a generally positive analyst outlook.
• Third-quarter revenue rose 10.3% to $17.4 billion and adjusted EPS reached $3.82, beating estimates as Skyrizi, Rinvoq and neuroscience products offset declining Humira sales. AbbVie also raised its outlook and increased its quarterly dividend 5.2% to $1.82 per share.
• Analysts remain broadly bullish, with several firms raising price targets as high as $346 and MarketBeat reporting a “Moderate Buy” consensus. However, investors remain concerned about valuation and whether AbbVie’s newer growth products can sustain momentum through the Humira transition.

AbbVie Inc. (NYSE:ABBV - Get Free Report)'s stock price dropped 2.1% during trading on Monday. The company traded as low as $286.14 and last traded at $288.6560. 8,834,601 shares changed hands during trading, an increase of 39% from the average session volume of 6,341,916 shares. The stock had previously closed at $294.89.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Expanded migraine partnership: AbbVie and Brise Pharmaceuticals signed a global license agreement to develop next-generation migraine therapies. The deal could be worth up to approximately $757 million, adding another potential growth opportunity to AbbVie’s neuroscience pipeline. AbbVie, Brise Expand Migraine Drug Partnership
• Positive Sentiment: Positive Phase 3 migraine results: AbbVie reported a Phase 3 study win published in The Lancet Neurology, supporting the potential of its migraine treatment portfolio and strengthening its neuroscience growth outlook. AbbVie Lands Phase 3 Migraine Study Win
• Positive Sentiment: Analysts raised price targets: Cantor Fitzgerald increased its target to $325, RBC to $330, Canaccord Genuity to $338, Leerink Partners to $342 and Morgan Stanley to $346. The upgrades followed AbbVie’s stronger-than-expected third-quarter results and improved outlook. Analysts Increase Their Forecasts on AbbVie
• Positive Sentiment: Growth transition remains on track: Third-quarter revenue rose 10.3% to $17.4 billion, while adjusted EPS of $3.82 exceeded expectations. Skyrizi, Rinvoq and neuroscience products offset Humira’s decline, and AbbVie raised its 2026 revenue and earnings outlook. ABBV Q3 Earnings Call Highlights
• Positive Sentiment: Dividend increased: AbbVie raised its quarterly dividend 5.2% to $1.82 per share, or $7.28 annually, reinforcing its appeal to income-focused investors.
• Neutral Sentiment: Legal win over drug pricing: AbbVie prevailed in a lawsuit against the U.S. Department of Health and Human Services concerning drug price controls. The ruling may preserve pricing flexibility, although the longer-term regulatory outlook remains uncertain. AbbVie Wins Drug Price Control Lawsuit
• Negative Sentiment: Valuation and transition concerns: Although Skyrizi and Rinvoq are replacing Humira revenue, investors remain focused on whether AbbVie’s newer growth engines can sustain momentum as Humira fades. The stock’s recent rally and high valuation may also be encouraging short-term profit-taking.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. BNP Paribas Exane upped their target price on shares of AbbVie from $218.00 to $247.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 11th. Scotiabank raised their target price on shares of AbbVie from $280.00 to $320.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 6th. Weiss Ratings upgraded shares of AbbVie from a "buy (b-)" rating to a "buy (b)" rating in a research report on Thursday, October 8th. Royal Bank Of Canada raised their price objective on shares of AbbVie from $280.00 to $330.00 and gave the stock an "outperform" rating in a research note on Monday. Finally, Leerink Partners upped their target price on AbbVie from $309.00 to $342.00 and gave the company an "outperform" rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $293.29.

AbbVie Stock Performance

The company has a market cap of $510.00 billion, a price-to-earnings ratio of 49.68, a price-to-earnings-growth ratio of 1.35 and a beta of 0.24. The stock's fifty day simple moving average is $269.35 and its two-hundred day simple moving average is $237.23.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping analysts' consensus estimates of $3.73 by $0.09. AbbVie had a negative return on equity of 435.41% and a net margin of 15.67%. The business had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. During the same period in the prior year, the firm posted $1.86 EPS. The business's revenue for the quarter was up 10.3% on a year-over-year basis. Analysts predict that AbbVie Inc. will post 13.92 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be given a dividend of $1.82 per share. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. This is an increase from AbbVie's previous quarterly dividend of $1.73. AbbVie's dividend payout ratio is currently 119.10%.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company's stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.06% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Burk Holdings LLC acquired a new position in shares of AbbVie during the second quarter valued at approximately $30,000. Marquette Asset Management LLC raised its stake in shares of AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company's stock worth $35,000 after buying an additional 48 shares in the last quarter. IMG Wealth Management Inc. lifted its holdings in shares of AbbVie by 3,060.0% in the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company's stock valued at $40,000 after buying an additional 153 shares during the period. Principia Wealth Advisory LLC boosted its stake in AbbVie by 38.9% during the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company's stock valued at $40,000 after buying an additional 44 shares in the last quarter. Finally, Tacita Capital Inc bought a new position in AbbVie during the second quarter valued at about $42,000. 70.23% of the stock is owned by institutional investors and hedge funds.

About AbbVie

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.